WO2007067780A3 - Combination therapy and antibody panels - Google Patents

Combination therapy and antibody panels Download PDF

Info

Publication number
WO2007067780A3
WO2007067780A3 PCT/US2006/047077 US2006047077W WO2007067780A3 WO 2007067780 A3 WO2007067780 A3 WO 2007067780A3 US 2006047077 W US2006047077 W US 2006047077W WO 2007067780 A3 WO2007067780 A3 WO 2007067780A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
combination immunotherapy
combination therapy
idiotypic
administration
Prior art date
Application number
PCT/US2006/047077
Other languages
French (fr)
Other versions
WO2007067780A2 (en
Inventor
Dan W Denney
Keri Marie Tate
Thomas P Theriault
Original Assignee
Genitope Corp
Dan W Denney
Keri Marie Tate
Thomas P Theriault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/297,168 external-priority patent/US20070134249A1/en
Priority claimed from US11/297,167 external-priority patent/US20070134248A1/en
Application filed by Genitope Corp, Dan W Denney, Keri Marie Tate, Thomas P Theriault filed Critical Genitope Corp
Priority to CA002632744A priority Critical patent/CA2632744A1/en
Publication of WO2007067780A2 publication Critical patent/WO2007067780A2/en
Publication of WO2007067780A3 publication Critical patent/WO2007067780A3/en
Priority to GB0812408A priority patent/GB2448627B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention is related to combination immunotherapy for malignancies such as Non-Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody, or antibody fragment, directed to a non-idiotypic portion of an immunoglobulin or immunoglobulin-like molecule expressed on the surface of a malignant cell (e.g., a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same malignant cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.
PCT/US2006/047077 2005-12-08 2006-12-08 Combination therapy and antibody panels WO2007067780A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002632744A CA2632744A1 (en) 2005-12-08 2006-12-08 Combination therapy and antibody panels
GB0812408A GB2448627B (en) 2005-12-08 2008-07-07 Combination therapy and antibody panels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/297,168 US20070134249A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
US11/297,167 US20070134248A1 (en) 2005-12-08 2005-12-08 Combination therapy and antibody panels
US11/297,167 2005-12-08
US11/297,168 2005-12-08

Publications (2)

Publication Number Publication Date
WO2007067780A2 WO2007067780A2 (en) 2007-06-14
WO2007067780A3 true WO2007067780A3 (en) 2008-05-02

Family

ID=38123554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047077 WO2007067780A2 (en) 2005-12-08 2006-12-08 Combination therapy and antibody panels

Country Status (3)

Country Link
CA (1) CA2632744A1 (en)
GB (1) GB2448627B (en)
WO (1) WO2007067780A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922212B1 (en) * 2007-10-11 2011-11-11 France Etat ANTIBODY ANTIBODY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US20030129628A1 (en) * 1992-03-09 2003-07-10 Sybille Muller Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVIS ET AL.: "Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradication the Malignant Clone", BLOOD, vol. 92, August 1998 (1998-08-01), pages 1184 - 1190 *
NELSON ET AL.: "Tumor - Specific, Cytotoxic T-Lymphocyte Response After Idiotype Vaccination for B-cell, Non-Hodgkin's Lymphoma", BLOOD, vol. 88, July 1996 (1996-07-01), pages 580 - 589 *
RUFFINI ET AL.: "Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines", HAEMATOLOGICA, vol. 87, September 2002 (2002-09-01), pages 989 - 1001 *

Also Published As

Publication number Publication date
CA2632744A1 (en) 2007-06-14
WO2007067780A2 (en) 2007-06-14
GB0812408D0 (en) 2008-08-13
GB2448627A (en) 2008-10-22
GB2448627B (en) 2010-07-14

Similar Documents

Publication Publication Date Title
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
ATE535547T1 (en) CROSS-LINKED ANTIBODIES
WO2005103081A3 (en) Human monoclonal antibodies against cd20
ATE530577T1 (en) EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
WO2008053330A3 (en) Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
IL245462A0 (en) Humanized anti-cmet antagonists
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
TW200510459A (en) RG1 antibodies and uses thereof
WO2009054863A3 (en) Human antibodies that bind cd19 and uses thereof
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
WO2007000671A3 (en) Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
WO2006117782A3 (en) Recombinant antibodies against cd55 and cd59 and uses thereof
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
DE602005016773D1 (en) ANTIBODY ANTIBODIES WITH REDUCED COMPLEMENT FIXATION
AU6760700A (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
WO2006076525A3 (en) Combination cancer therapy with anti-psma antibodies
WO2007075921A3 (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)
WO2009126817A3 (en) Ige antibodies for the treatment of cancer
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2632744

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 0812408.3

Country of ref document: GB

Ref document number: 812408

Country of ref document: GB

Ref document number: 0812408

Country of ref document: GB

122 Ep: pct application non-entry in european phase

Ref document number: 06845134

Country of ref document: EP

Kind code of ref document: A2